Mark Farrah Associates Analyzed the 2024 Medicare Supplement Market
CANONSBURG, Pa.--(BUSINESS WIRE)--In the latest Healthcare Business Strategy report, Mark Farrah Associates (MFA), www.markfarrah.com provided an overview of the 2024 Medicare Supplement market with insights about competitive positioning and standardized plan type preferences. Medicare Supplement plans, also known as Medigap or Med Supp plans, covered over 13.54 million seniors as of December 31, 2024, representing a year-over-year enrollment decline of 0.3%. Many leading managed care organizations, Blues plans, regional plans, and multiline carriers compete in the Medicare Supplement space.
Highlights Include:
MFA's assessment of standardized plan type preferences for 2024 found Plan G remained the most popular plan type, enrolling approximately 5.7 million members.
Approximately 4.5 million Med Supp members were enrolled in Plan F and accounted for 30% of the market in 2024.
Medicare Supplement plans collectively earned approximately $37 billion in premiums and paid out $31.3 billion in claims during 2024.
The aggregate loss ratio (incurred claims as a percentage of earned premiums) was 84.4% as of December 2024.
UnitedHealth continued to lead in this segment with 4.3 million members and covered 32% of the market as of December 31, 2024.
To read the FREE full text of " Medicare Supplement Enrollment Down Slightly in 2024", visit the MFA Briefs on Mark Farrah Associates' website. You can also follow us on LinkedIn.
About Med Supp Market Data
Med Supp Market Data, a Health Coverage Portal option offered by Mark Farrah Associates, presents the latest market share and financial performance data for Medicare Supplement plans. The product includes state-by-state membership, premiums, claims and loss ratios for plans nationwide. Online tables also include claims contacts as reported in the financial statements as filed with the National Association of Insurance Commissioners (NAIC). California managed care plans do not file financial statements with the NAIC and are not included in this analysis. For more information about Med Supp Market Data, please visit our website (www.markfarrah.com) or call 724.338.4100.
MFA is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. Committed to simplifying analysis of health insurance business, our products include: Health Coverage Portal™, Medicare Business Online™, Medicare Benefits Analyzer™, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. (ZTS) on Best Anchor Stocks' Substack. In this article, we will summarize the bulls' thesis on ZTS. Zoetis Inc. (ZTS)'s share was trading at $161.97 as of 22nd May. ZTS's trailing and forward P/E were 29.08 and 26.18 respectively according to Yahoo Finance. Syda Productions/ Zoetis (ZTS) reported mixed earnings that triggered a 5% sell-off, though the stock partially recovered the next day. While headline numbers were not disastrous, underlying concerns justified the reaction. Operational revenue grew 9%, but reported revenue rose just 1% due to FX headwinds and the recent divestiture of the low-margin MFA business, which ironically improved margins—gross margin expanded by 140 bps and operating margin by 150 bps. The company's capital return strategy remains robust, with buybacks accounting for 83% of free cash flow over the past year and a 2.4% year-over-year reduction in share count, boosting EPS growth above net income. Despite this, organic growth decelerated slightly, largely due to weaker-than-expected adoption of Librela, Zoetis' osteoarthritis pain monoclonal antibody. Though Librela posted 17% U.S. growth, management acknowledged slow uptake from poor awareness and macro pressures, leading to a downward revision of operational net income guidance. This is troubling, given Librela's previously expected outsized contribution to future growth and margins. However, Zoetis unveiled a new, long-acting OA pain MAB in the pipeline—administered quarterly, with fewer side effects and a distinct brand—which could reset the narrative if approved in late 2025. Meanwhile, core franchises in parasiticides and dermatology (Simparica and Apoquel) continue to post double-digit growth despite rising competition. The shift toward retail, now 21% of U.S. sales, enhances reach but slightly dilutes the vet-driven moat. Ultimately, while near-term execution challenges around Librela weigh on sentiment, Zoetis' market leadership, innovation pipeline, and structural tailwinds support a favorable long-term outlook. We have previously covered Zoetis Inc. (ZTS) in December 2024 wherein we summarized a bull thesis by Business Model Mastery on Substack. The author highlighted Zoetis (ZTS) as a top play on the booming pet care market. Since then, the company has delivered strong Q3 results, led by blockbuster osteoarthritis and dermatology treatments, retail expansion, and global growth. With rising chronic care demand and diagnostics adoption, ZTS remains a long-term compounder. Zoetis Inc. (ZTS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 76 hedge fund portfolios held ZTS at the end of the fourth quarter which was 62 in the previous quarter. While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ZTS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
5 days ago
- Yahoo
House passes bill to eliminate investment cap requested by FM
The Rhode Island House voted 71-0 Tuesday, May 27, 2025, to approve a bill repealing caps on alternative investments for local insurance companies. (Screenshot/Capitol TV) A state policy change aimed at helping Johnston insurance company FM expand its investments, and potentially, its employment in Rhode Island, sailed through the Rhode Island House of Representatives Tuesday. The 71-0 vote came without discussion, following a strong backing by Rep. Joseph Solomon, chairman of the House Committee on Commerce, which held a May 15 hearing on the bill. 'It's a great bill,' said Solomon, a Warwick Democrat, noting that no written or verbal opposition on the proposal emerged during the hearing before the House panel. The bill sponsored by Rep. Alex Finkelman, a Jamestown Democrat, was introduced on May 8 after FM executives met with House Speaker K. Joseph Shekarchi. The Fortune 500 company was formerly known as FM Global, but rebranded in July 2024. The proposed policy change seeks to let insurance companies invest as much as they want in nontraditional or alternative assets — referred to under federal reporting requirements as Schedule BA assets — like hedge funds, private equity funds and real estate holdings. It effectively reverses the 1984 law on the books, which limited investments on long-term assets outside of traditional stocks and bonds to no more than 10% of a company's total assets. Eleventh hour insurance bill could help top employer FM expand in R.I. The origins of the 1984 law remain somewhat hazy, but proponents for its repeal insist the rule no longer makes sense, with alternative investments like hedge funds now widely used and commonly accepted. 'When this law was enacted in 1984, the limitation was practical, as regulatory techniques for overseeing insurance investments were more limited at that time,' Solomon said Tuesday. 'The law is now outdated.' Since 2010, insurance companies have been steadily increasing investments in alternative assets, searching for higher returns in a low-interest rate environment. The appeal of alternate asset classes increased further after 2017 regulatory changes adopted by the National Association of Insurance Commissioners (NAIC), which reformed how companies could record exchange-traded funds on their balance sheets. Certain bonds are also now considered Schedule BA assets under a new NAIC effective Jan. 1. Removing the state's limit on BA investments now is particularly timely,' Jonathan Schreiber, associate vice president of state government relations for the American Property Casualty Insurance Association, wrote in a May 15 letter to lawmakers. The change would also put Rhode Island in line with neighboring Massachusetts and Connecticut — a key selling point for Gov. Dan McKee, who has already signaled support for the policy change. Especially as the state wrestles with how to retain major employers like Hasbro, Inc., which previously indicated it was looking to abandon its Pawtucket headquarters in favor of a new location in Boston. The potential relocation was put on hold after Trump tariffs roiled markets and put company profits at risk; an update is now expected sometime this summer. FM executives made it clear they have no intention of picking up and moving from their 8-acre Johnston headquarters, which houses the bulk of the property insurer's 1,500-person local workforce. Instead, the company is contemplating more hiring as it looks to expand its offerings of research, development and industrial and commercial insurance products for renewable energy, Finkelman said previously. FM did not offer specifics on expansion plans when asked by Rhode Island Current. Lifting the investment cap could also benefit the other 29 local insurance companies that operate in Rhode Island, according to Elizabeth Dwyer, director for the Department of Business Regulation. Dwyer wrote a letter supporting the policy change, noting that state business regulators will continue to carefully monitor companies. 'This vigilance gives me confidence that a blunt tool for investments is no longer necessary,' Dwyer wrote in the May 14 letter to lawmakers. Lincoln-based Amica Mutual Insurance Co. and Providence's Delta Dental of Rhode Island also submitted written support for the policy change, along with the Rhode Island Business Coalition and the National Association of Mutual Insurance Companies. A companion bill in the Senate, sponsored by Johnston Democrat Andrew Dimitri, remains under review by the Senate Committee on Finance following an initial May 20 hearing. A committee vote has not been scheduled as of Tuesday, according to Greg Pare, a Senate spokesperson. If passed by both chambers and signed into law by McKee, the investment cap would be repealed immediately. Reps. Arthur Handy, Brian Kennedy, Earl Read III and Brandon Voas were not present for the House vote Tuesday. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
5 days ago
- Yahoo
Mark Farrah Associates Analyzed the 2024 Medicare Supplement Market
CANONSBURG, Pa., May 28, 2025--(BUSINESS WIRE)--In the latest Healthcare Business Strategy report, Mark Farrah Associates (MFA), provided an overview of the 2024 Medicare Supplement market with insights about competitive positioning and standardized plan type preferences. Medicare Supplement plans, also known as Medigap or Med Supp plans, covered over 13.54 million seniors as of December 31, 2024, representing a year-over-year enrollment decline of 0.3%. Many leading managed care organizations, Blues plans, regional plans, and multiline carriers compete in the Medicare Supplement space. Highlights Include: MFA's assessment of standardized plan type preferences for 2024 found Plan G remained the most popular plan type, enrolling approximately 5.7 million members. Approximately 4.5 million Med Supp members were enrolled in Plan F and accounted for 30% of the market in 2024. Medicare Supplement plans collectively earned approximately $37 billion in premiums and paid out $31.3 billion in claims during 2024. The aggregate loss ratio (incurred claims as a percentage of earned premiums) was 84.4% as of December 2024. UnitedHealth continued to lead in this segment with 4.3 million members and covered 32% of the market as of December 31, 2024. To read the FREE full text of "Medicare Supplement Enrollment Down Slightly in 2024", visit the MFA Briefs on Mark Farrah Associates' website. You can also follow us on LinkedIn. About Med Supp Market Data Med Supp Market Data, a Health Coverage Portal option offered by Mark Farrah Associates, presents the latest market share and financial performance data for Medicare Supplement plans. The product includes state-by-state membership, premiums, claims and loss ratios for plans nationwide. Online tables also include claims contacts as reported in the financial statements as filed with the National Association of Insurance Commissioners (NAIC). California managed care plans do not file financial statements with the NAIC and are not included in this analysis. For more information about Med Supp Market Data, please visit our website ( or call 724.338.4100. About Mark Farrah Associates (MFA) MFA is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. Committed to simplifying analysis of health insurance business, our products include: Health Coverage Portal™, Medicare Business Online™, Medicare Benefits Analyzer™, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus. View source version on Contacts Mark Farrah AssociatesAnn Marie Wolfe, amwolfe@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
